申请人:Eggenweiler Hans-Michael
公开号:US20050176714A1
公开(公告)日:2005-08-11
Pyridazine derivatives of the formula (I) act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
式(I)的哒嗪衍生物是磷酸二酯酶 IV 抑制剂,可用于治疗骨质疏松症、肿瘤、恶病质、动脉粥样硬化、类风湿性关节炎、多发性硬化、糖尿病、炎症过程、过敏、哮喘、自身免疫性疾病、心肌疾病和艾滋病。